Acute D2/D3 Dopaminergic Agonism but Chronic D2/D3 Antagonism Prevents NMDA Antagonist Neurotoxicity

Biological Psychiatry

Volumn 60, Issue 6, 2006, Pages 630-638

  Farber, Nuri B ^a   Nemmers, Brian ^a   Noguchi, Kevin K ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Antipsychotics; D2 D3 dopaminergic agents; disinhibition; neurotoxicity; NMDA antagonists; psychosis

Indexed keywords

10,11 DIHYDROXY N,N PROPYLNORAPOMORPHINE; 2 DIPROPYLAMINO 5,6 DIMETHOXYINDAN; 4 PHOSPHONOMETHYLPIPECOLIC ACID; APOMORPHINE; BROMOCRIPTINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; DOPAMINE 2 RECEPTOR STIMULATING AGENT; DOPAMINE 3 RECEPTOR BLOCKING AGENT; DOPAMINE 3 RECEPTOR STIMULATING AGENT; HALOPERIDOL; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; AMINO ACID RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR BLOCKING AGENT; DOPAMINE RECEPTOR STIMULATING AGENT; PIPECOLIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DOSE REGIMEN; FEMALE; LONG TERM CARE; NEUROPROTECTION; NEUROTOXICITY; NONHUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PSYCHOSIS; RAT; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG ADMINISTRATION; DRUG INTERACTION; SPRAGUE DAWLEY RAT; TOXICITY AND INTOXICATION;

ANIMALS; DISEASE MODELS, ANIMAL; DOPAMINE AGONISTS; DOPAMINE ANTAGONISTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG INTERACTIONS; EXCITATORY AMINO ACID ANTAGONISTS; FEMALE; NEUROTOXICITY SYNDROMES; PIPECOLIC ACIDS; RATS; RATS, SPRAGUE-DAWLEY;

EID: 33748742809     PISSN: 00063223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biopsych.2006.02.019     Document Type: Article

References (75)

1. Agid O., Kapur S., Arenovich T., and Zipursky R.B. Delayed-onset hypothesis of antipsychotic action: a hypothesis tested and rejected. Arch Gen Psychiatry 60 (2003) 1228-1235
2. Allen H.L., and Iversen L.L. Phencyclidine, dizocilpine, and cerebrocortical neurons. Science 247 (1990) 221
3. Anand A., Charney D.S., Oren D.A., Berman R.M., Hu X.S., Cappiello A., et al. Attenuation of the neuropsychiatric effects of ketamine with lamotrigine. Arch Gen Psychiatry 57 (2000) 270-276
4. Audinot V., Newman-Tancredi A., Gobert A., Rivet J.M., Brocco M., Lejeune F., et al. A comparative in vitro and in vivo pharmacological characterization of the novel dopamine D3 receptor antagonists (+)-S 14297, nafadotride, GR 103,691 and U 99194. J Pharmacol Exp Ther 287 (1998) 187-197
5. Bell D.S. The experimental reproduction of amphetamine psychosis. Arch Gen Psychiatry 29 (1973) 35-40
6. Brady K.T., Lydiard R.B., Malcolm R., and Ballenger J.C. Cocaine-induced psychosis. J Clin Psychiatry 52 (1991) 509-512
7. Castren E., Da Phena Berzaghi M., Lindholm D., and Thoenen H. Differential effects of MK-801 on brain-derived neurotrophic factor mRNA levels in different regions of the rat brain. Exp Neurol 122 (1993) 244-252
8. Chen S., and Diamond J.S. Synaptically released glutamate activates extrasynaptic NMDA receptors on cells in the ganglion cell layer of rat retina. J Neurosci 22 (2002) 2165-2173
9. Cloninger C.R. The discovery of susceptibility genes for mental disorders. Proc Natl Acad Sci USA 99 (2002) 13365-13367
10. Corso T.D., Sesma M.A., Tenkova T.I., Der T.C., Wozniak D.F., Farber N.B., et al. Multifocal brain damage induced by phencyclidine is augmented by pilocarpine. Brain Res 752 (1997) 1-14
11. Diamond J.S. A broad view of glutamate spillover. Nat Neurosci 5 (2002) 291-292
12. Domino E.F., and Luby E.D. Abnormal mental states induced by phencyclidine as a model of schizophrenia. In: Domino E.F. (Ed). PCP (Phencyclidine): Historical and current perspectives (1981), NPP Books, Ann Arbor 401-418
13. Dragunow M., and Faull R.L.M. MK-801 induces c-fos protein in thalamic and neocortical neurons of rat brain. Neurosci Lett 111 (1990) 39-45
14. Duncan G.E., Miyamoto S., and Lieberman J.A. Chronic administration of haloperidol and olanzapine attenuates ketamine-induced brain metabolic activation. J Pharmacol Exp Ther 305 (2003) 999-1005
15. Ellinwood Jr. E.H., Sudilovsky A., and Nelson L.M. Evolving behavior in the clinical and experimental amphetamine (model) psychosis. Am J Psychiatry 130 (1973) 1088-1093
16. Ellison G. Competitive and non-competitive NMDA antagonists induce similar limbic degeneration. Neuroreport 5 (1994) 2688-2692
17. Ellison G., and Switzer R.C. Dissimilar patterns of degeneration in brain following four different addictive stimulants. Neuroreport 5 (1993) 17-20
18. Farber N.B. The NMDA receptor hypofunction model of psychosis. Ann NY Acad Sci 1003 (2003) 119-130
19. 2 adrenergic agonists prevent MK-801 neurotoxicity. Neuropsychopharmacology 12 (1995) 347-349
20. Farber N.B., Foster J., and Olney J.W. Clozapine and related analogs block NMDA antagonist neurotoxicity: Implications for schizophrenia. Schizophr Res 15 (1995) 57-58
21. 2A receptors prevent NMDA antagonist neurotoxicity. Neuropsychopharmacology 18 (1998) 57-62
22. Farber N.B., Jiang X., Dikranian K., and Nemmers B. Muscimol prevents NMDA antagonist neurotoxicity by activating GABAA receptors in several brain regions. Brain Res 993 (2003) 90-100
23. Farber N.B., Jiang X.P., Heinkel C., and Nemmers B. Antiepileptic drugs and agents that inhibit voltage-gated sodium channels prevent NMDA antagonist neurotoxicity. Mol Psychiatry 7 (2002) 726-733
24. Farber N.B., Kim S.H., Dikranian K., Jiang X.P., and Heinkel C. Receptor mechanisms and circuitry underlying NMDA antagonist neurotoxicity. Mol Psychiatry 7 (2002) 32-43
25. Farber N.B., Price M.T., Labruyere J., Nemnich J., St Peter H., Wozniak D.F., et al. Antipsychotic drugs block phencyclidine receptor-mediated neurotoxicity. Biol Psychiatry 34 (1993) 119-121
26. Farber N.B., Wozniak D.F., Price M.T., Labruyere J., Huss J., St Peter H., et al. Age specific neurotoxicity in the rat associated with NMDA receptor blockade: potential relevance to schizophrenia?. Biol Psychiatry 38 (1995) 788-796
27. Fix A.S., Horn J.W., Wightman K.A., Johnson C.A., Long G.G., Storts R.W., et al. Neuronal vacuolization and necrosis induced by the noncompetitive N-methyl-D-aspartate (NMDA) antagonist MK(+)801 (dizocilpine maleate): a light and electron microscopic evaluation of the rat retrosplenial cortex. Exp Neurol 123 (1993) 204-215
28. Gao X.M., Hashimoto T., and Tamminga C.A. Phencyclidine (PCP) and Dizocilpine (MK801) exert time-dependent effects on the expresion of immediate early genes in rat brain. Synapse 29 (1998) 14-28
29. Gass P., Herdegen T., Bravo R., and Kiessling M. Induction and suppression of immediate early genes in specific rat brain regions by the non-competitive N-methyl-D-aspartate antagonist, MK-801. Neuroscience 53 (1993) 749-758
30. Giovannini M.G., Mutolo D., Bianchi L., Michelassi A., and Pepeu G. NMDA receptor antagonists decrease GABA outflow from the septum and increase acetylcholine outflow from the hippocampus: a microdialysis study. J Neurosci 14 (1994) 1358-1365
31. Handa F., Tanaka M., Nishikawa T., and Toyooka H. Effects of oral clonidine premedication on side effects of intravenous ketamine anesthesia: a randomized, double-blind, placebo-controlled study. J Clin Anesth 12 (2000) 19-24
32. Horvath Z.C., Czopf J., and Buzsaki G. MK-801-induced neuronal damage in rats. Brain Res 753 (1997) 181-195
33. Hughes P., Dragunow M., Beilharz E., Lawlor P., and Gluckman P. MK801 induces immediate-early gene proteins and BDNF mRNA in rat cerebrocortical neurones. NeuroReport 4 (1993) 183-186
34. Javitt D.C., and Zukin S.R. Recent advances in the phencyclidine model of schizophrenia. Am J Psychiatry 148 (1991) 1301-1308
35. Jevtovic-Todorovic V., Kirby C.O., and Olney J.W. Isoflurane and propofol block neurotoxicity caused by MK-801 in the rat posterior cingulate/retrosplenial cortex. J Cereb Blood Flow Metab 17 (1997) 168-174
36. Kalivas P.W., and Duffy P. Dopamine regulation of extracellular glutamate in the nucleus accumbens. Brain Res 761 (1997) 173-177
37. Kane J.M., Schooler N.R., Marder S.R., Simpson G.M., and Casey D.E. Methods for Clinical Evaluation of Pharmacologic Treatments of Schizophrenia. In: Prien R.F., and Robinson D.S. (Eds). Clinical Evaluation of Psychotropic Drugs (1994), Raven Press, LTD, New York 345-380
38. Kapur S., Arenovich T., Agid O., Zipursky R., Lindborg S., and Jones B. Evidence for onset of antipsychotic effects within the first 24 hours of treatment. Am J Psychiatry 162 (2005) 939-946
39. 2-adrenergic agonists. Mol Psychiatry 4 (1999) 344-352
40. Koga E., and Momiyama T. Presynaptic dopamine D2-like receptors inhibit excitatory transmission onto rat ventral tegmental dopaminergic neurones. J Physiol 523 (2000) 163-173 Pt 1
41. Krystal J.H., D'Souza D.C., Karper L.P., Bennett A., Abi-Dargham A., Abi-Saab D., et al. Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology 145 (1999) 193-204
42. Kurumaji A., and McCulloch J. Effects of MK-801 upon local cerebral glucose utilisation in conscious rats and in rats anaesthetised with halothane. J Cereb Blood Flow Metab 9 (1989) 786-794
43. Lahti A.C., Koffel B., LaPorte D.J., and Tamminga C.A. Subanesthetic doses of ketamine stimulate psychosis in schizophrenia. Neuropsychopharmacology 13 (1995) 9-19
44. Leucht S., Busch R., Hamann J., Kissling W., and Kane J.M. Early-onset hypothesis of antipsychotic drug action: a hypothesis tested, confirmed and extended. Biol Psychiatry 57 (2005) 1543-1549
45. Levanen J., Makela M.L., and Scheinin H. Dexmedetomidine premedication attenuates ketamine-induced cardiostimulatory effects and postanesthetic delirium. Anesthesiology 82 (1995) 1117-1125
46. Levant B. The D3 dopamine receptor: neurobiology and potential clinical relevance. Pharmacol Rev 49 (1997) 231-252
47. Malhotra A.K., Adler C.M., Kennison S.D., Elman I., Pickar D., and Breier A. Clozapine blunts N-methyl-D-aspartate antagonist-induced psychosis: a study with ketamine. Biol Psychiatry 42 (1997) 664-668
48. Meibach R.C., Glicks D., Cox R., and Maayani S. Localisation of phencyclidine-induced changes in brain energy metabolism. Nature 282 (1979) 625-626
49. Moghaddam B., Adams B., Verma A., and Daly D. Activation of glutamatergic neurotransmission by ketamine: a novel step in the pathway from NMDA receptor blockade to dopaminergic and cognitive disruptions associated with the prefrontal cortex. J Neurosci 17 (1997) 2921-2927
50. Nakao S.I., Adachi T., Murakawa M., Shinomura T., Kurata J., Shichino T., et al. Halothane and diazepam inhibit ketamine-induced c-fos expression in the rat cingulate cortex. Anesthesiology 85 (1996) 874-882
51. Nakki R., Sharp F.R., Sagar S.M., and Honkaniemi J. Effects of phencyclidine on immediate early gene expression in the brain. J Neurosci Res 45 (1996) 13-27
52. Nelsom S.R., Howard R.B., Cross R.S., and Samson F. Ketamine-induced changes in regional glucose utilization in the rat brain. Anesthesiology 52 (1980) 330-334
53. Newcomer J.W., Farber N.B., Selke G., Melson A.K., Jevtovic-Todorovic V., and Olney J.W. Guanabenz effects on NMDA antagonist-induced mental symptoms in humans. Abstr. Soc. Neurosci 24 (1998) 525
54. Noguchi K.K., Nemmers B., and Farber N.B. Age has a similar influence on the susceptibility to NMDA antagonist-induced neurodegeneration in most brain regions. Brain Res Dev Brain Res 158 (2005) 82-91
55. Okamura N., Hashimoto K., Shimizu E., Koike K., Ohgake S., Koizumi H., et al. Protective effect of LY379268, a selective group II metabotropic glutamate receptor agonist, on dizocilpine-induced neuropathological changes in rat retrosplenial cortex. Brain Res 992 (2003) 114-119
56. Okamura N., Hashimoto K., Shimizu E., Kumakiri C., Komatsu N., and Iyo M. Adenosine A1 receptor agonists block the neuropathological changes in rat retrosplenial cortex after administration of the NMDA receptor antagonist dizocilpine. Neuropsychopharmacology 29 (2004) 544-550
57. Olney J.W., and Farber N.B. Glutamate receptor dysfunction and schizophrenia. Arch Gen Psychiatry 52 (1995) 998-1007
58. Olney J.W., Labruyere J., and Price M.T. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs. Science 244 (1989) 1360-1362
59. Olney J.W., Labruyere J., Wang G., Wozniak D.F., Price M.T., and Sesma M.A. NMDA antagonist neurotoxicity: mechanism and prevention. Science 254 (1991) 1515-1518
60. Paxinos G., and Watson C. The rat brain in stereotaxic coordinates. 4th ed. (1998), Academic Press, New York
61. Rabinowitz J., Hornik T., and Davidson M. Rapid onset of therapeutic effect of risperidone versus haloperidol in a double-blind randomized trial. J Clin Psychiatry 62 (2001) 343-346
62. Reich D.L., and Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 36 (1989) 186-197
63. Richtand N.M., Woods S.C., Berger S.P., and Strakowski S.M. D3 dopamine receptor, behavioral sensitization, and psychosis. Neurosci Biobehav Rev 25 (2001) 427-443
64. Satel S.L., Southwick S.M., and Gawin F.H. Clinical features of cocaine-induced paranoia. Am J Psychiatry 148 (1991) 495-498
65. Sato M., Chen C.C., Akiyama K., and Otsuki S. Acute exacerbation of paranoid psychotic state after long-term abstinence in patients with previous methamphetamine psychosis. Biol Psychiatry 18 (1983) 429-440
66. Sautel F., Griffon N., Levesque D., Pilon C., Schwartz J.C., and Sokoloff P. A functional test identifies dopamine agonists selective for D3 versus D2 receptors. Neuroreport 6 (1995) 329-332
67. Sax K.W., and Strakowski S.M. Behavioral sensitization in humans. J Addict Dis 20 (2001) 55-65
68. Seeman P., Lee T., Chau-Wong M., and Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature 261 (1976) 717-719
69. Sharp F.R., Jasper P., Hall J., Noble L., and Sagar S.M. MK-801 and ketamine induce heat shock protein HSP72 in injured neurons in posterior cingulate and retrosplenial cortex. Ann Neurol 30 (1991) 801-809
70. Strange P.G. Antipsychotic drugs: importance of dopamine receptors for mechanisms of therapeutic actions and side effects. Pharmacol Rev 53 (2001) 119-133
71. Tzschentke T.M. Pharmacology and behavioral pharmacology of the mesocortical dopamine system. Prog Neurobiol 63 (2001) 241-320
72. Waters N., Svensson K., Haadsma-Svensson S.R., Smith M.W., and Carlsson A. The dopamine D3-receptor: a postsynaptic receptor inhibitory on rat locomotor activity. J Neural Transm Gen Sect 94 (1993) 11-19
73. White P.F., Way W.L., and Trevor A.J. Ketamine-its pharmacology and therapeutic uses. Anesthesiology 56 (1982) 119-136
74. Wozniak D.F., Dikranian K., Ishimaru M., Nardi A., Corso T.D., Tenkova T., et al. Disseminated corticolimbic neuronal degeneration induced in rat brain by MK-801: relevance to Alzheimer's disease. Neurobiology Dis 5 (1998) 305-322
75. Yamamoto B.K., and Davy S. Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J Neurochem 58 (1992) 1736-1742